These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 12507628

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors.
    Frank RN.
    Am J Ophthalmol; 2002 May; 133(5):693-8. PubMed ID: 11992868
    [Abstract] [Full Text] [Related]

  • 3. Treatment of diabetic retinopathy with protein kinase C subtype Beta inhibitor.
    Lang GE.
    Dev Ophthalmol; 2007 May; 39():157-165. PubMed ID: 17245085
    [Abstract] [Full Text] [Related]

  • 4. Rubosixtaurin and other PKC inhibitors in diabetic retinopathy and macular edema. Review.
    Gálvez MI.
    Curr Diabetes Rev; 2009 Feb; 5(1):14-7. PubMed ID: 19199893
    [Abstract] [Full Text] [Related]

  • 5. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.
    PKC-DRS2 GroupBeetham Eye Institute, Joslin Diabetes Center, 1 Joslin Place, Boston, MA 02215, USA. LPAiello@Joslin.Harvard.edu, Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, Sheetz MJ, Vignati L, Zhi XE.
    Ophthalmology; 2006 Dec; 113(12):2221-30. PubMed ID: 16989901
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Ruboxistaurin: LY 333531.
    Drugs R D; 2007 Dec; 8(3):193-9. PubMed ID: 17472415
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Role of PKC in the pathogenesis of diabetic vascular complications].
    Inoguchi T, Umeda F.
    Nihon Rinsho; 2002 Oct; 60 Suppl 10():67-72. PubMed ID: 12430209
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial.
    PKC-DMES Study Group.
    Arch Ophthalmol; 2007 Mar; 125(3):318-24. PubMed ID: 17353401
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [The role of protein kinase C in the pathophysiology of diabetic retinopathy].
    Lang GE, Kampmeier J.
    Klin Monbl Augenheilkd; 2002 Nov; 219(11):769-76. PubMed ID: 12494366
    [Abstract] [Full Text] [Related]

  • 17. Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2).
    Sheetz MJ, Aiello LP, Shahri N, Davis MD, Kles KA, Danis RP, Mbdv Study Group.
    Retina; 2011 Jun; 31(6):1053-9. PubMed ID: 21386766
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.